D. Boral Capital Reaffirms “Buy” Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued on Friday,Benzinga reports. They presently have a $29.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Imunon in a research report on Thursday, December 19th.

Imunon Price Performance

NASDAQ IMNN opened at $0.96 on Friday. The business has a 50 day moving average price of $0.86 and a 200 day moving average price of $1.02. The company has a market capitalization of $13.89 million, a P/E ratio of -0.51 and a beta of 2.04. Imunon has a 1-year low of $0.48 and a 1-year high of $3.65.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. During the same period in the previous year, the firm posted ($0.37) earnings per share. On average, research analysts expect that Imunon will post -1.68 earnings per share for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.